Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
8,31 USD | -4,59 % | -12,98 % | -.--% |
09/05 | IGM BIOSCIENCES, INC. : RBC Capital Markets da una recomendación de compra | ZM |
08/05 | IGM Biosciences, Inc. Proporciona orientación de ingresos para el segundo trimestre y el año completo 2024 | CI |
Resumen de negocios
Número de empleados: 216
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Engineered Immunoglobulin M Antibodies
100,0
%
| 1 | 100,0 % | 2 | 100,0 % | +99,25 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 1 | 100,0 % | 2 | 100,0 % | +99,25 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Fred Schwarzer
CEO | Chief Executive Officer | 72 | 01/02/03 |
Misbah Tahir
DFI | Director of Finance/CFO | 49 | 01/01/19 |
T. S. Harigopal
COO | Chief Operating Officer | - | 01/01/21 |
Chris Takimoto
CTO | Chief Tech/Sci/R&D Officer | 65 | 29/07/21 |
Bruce Keyt
CTO | Chief Tech/Sci/R&D Officer | 71 | 01/01/10 |
Lisa Wax
LAW | General Counsel | - | 01/01/21 |
Corporate Officer/Principal | - | 01/01/18 | |
George Gauthier
PRN | Corporate Officer/Principal | 52 | 12/04/21 |
Steven Weber
AUD | Comptroller/Controller/Auditor | 48 | 01/03/22 |
Paul Graffagnino
LAW | General Counsel | - | 01/01/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 26/01/21 |
M. Wilsey
BRD | Director/Board Member | 71 | 31/01/19 |
Fred Schwarzer
CEO | Chief Executive Officer | 72 | 01/02/03 |
Michael Lee
BRD | Director/Board Member | 45 | 01/07/19 |
Julie Hambleton
BRD | Director/Board Member | 66 | 15/08/18 |
Director/Board Member | 55 | 01/08/18 | |
Director/Board Member | 43 | 01/08/18 | |
William Strohl
BRD | Director/Board Member | 71 | 01/08/18 |
Director/Board Member | 49 | 03/10/23 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 25 386 983 | 0 | 0 | 37,37 % |
Acción B | 1 | 33 636 592 | 22 059 861 ( 65,58 %) | 0 |
Información de la empresa
IGM Biosciences, Inc.
325 East Middlefield Road
94043, Mountain View
+650 965 7873
http://www.igmbio.comSector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-.--% | 492 M | |
+11,60 % | 106 mil M | |
-4,68 % | 24,28 mil M | |
-0,82 % | 21,96 mil M | |
-10,12 % | 18,16 mil M | |
-42,12 % | 16,37 mil M | |
-17,47 % | 15,56 mil M | |
+2,77 % | 13,63 mil M | |
+34,58 % | 12,27 mil M | |
+77,64 % | 8873,08 M |
- Bolsa de valores
- Acciones
- Acción IGMS
- Empresa IGM Biosciences, Inc.